Overview

Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy

Status:
Completed

Trial end date:
2021-06-25

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether tanezumab is effective in the treatment of cancer pain due to bone metastasis in patients already taking background opioid therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Collaborator:

Eli Lilly and Company

Treatments:

Tanezumab